16 June 2014 | 14:44

Medical device maker Medtronic to buy Covidien for $42.9 bn

viewings icon comments icon

ПОДЕЛИТЬСЯ

whatsapp button telegram button facebook button
Medtronic Chairman and Chief Executive Omar Ishrak. ©Reuters/Brendan McDermid Medtronic Chairman and Chief Executive Omar Ishrak. ©Reuters/Brendan McDermid

US medical-device maker Medtronic will buy its Irish-based competitor Covidien for $42.9 billion, AFP reports according to the company said.

whatsapp button telegram button facebook button copyLink button
Иконка комментария блок соц сети

US medical-device maker Medtronic will buy its Irish-based competitor Covidien for $42.9 billion, AFP reports according to the company said.

The deal would allow Medtronic to take advantage of Ireland's lower business tax rates -- 12.5 percent versus 35 percent in the United States.

The cash-and-stock transaction is valued at $93.22 per Covidien share, or some $42.9 billion based on Medtronic's closing stock price of $60.70 per share on June 13, the statement read.

The combined company will have a broad product portfolio and some 87,000 employees in more than 150 countries.

Once the transaction is complete, "the businesses of Medtronic and Covidien will be combined under a new entity to be called Medtronic plc," the statement read.

"It will have its principal executive offices in Ireland, where Covidien's current headquarters resides and where both companies have a longstanding presence."

Medtronic plc however will continue to have its operational headquarters in Minneapolis, Minnesota, where the company currently employs more than 8,000 people.

"This acquisition will allow Medtronic to reach more patients, in more ways and in more places," said Medtronic Chairman and Chief Executive Officer Omar Ishrak.

Medtronic produces orthopedic and cardiovascular devices and is valued at around $61 billion, against $32 billion for Covidien, which focuses on devices used for surgery.

A number of US companies, in particular in the pharmaceutical industry, have recently launched bids to buy companies as a way to reduce their costs and tax burden and use their cash overseas.

Pfizer recently abandoned an attempt to buy British firm AstraZeneca for $117 billion in a deal that would have allowed the US company to take advantage of Britain's lower corporate tax rate.

The United States is considering amending its legislation to allow multinational companies to keep overseas indefinitely a portion of their profits in order to avoid paying US taxes on it.

Читайте также
Join Telegram Последние новости
The Moon is calling: New lunar mission
Wolf attacked man in Atyrau region
Euronews office opened in Astana
Earthquake recorded in Zhambyl region
Tokayev sent telegram to Qatar’s Emir
A New Year gift guide for her
Tokayev expressed condolences to Macron
Bitcoin exchange rate hit a new record
EU expanded sanctions against Belarus
Kazhydromet warned residents of Almaty
Лого TengriNews мобильная Лого TengriSport мобильная Лого TengriLife мобильная Лого TengriAuto мобильная Иконка меню мобильная
Иконка закрытия мобильного меню
Открыть TengriNews Открыть TengriLife Открыть TengriSport Открыть TengriTravel Открыть TengriGuide Открыть TengriEdu Открыть TengriAuto

Exchange Rates

 523.95  course up  543.16  course up  5.1  course up

 

Weather

 

Редакция Advertising
Социальные сети
Иконка Instagram footer Иконка Telegram footer Иконка Vkontakte footer Иконка Facebook footer Иконка Twitter footer Иконка Youtube footer Иконка TikTok footer Иконка WhatsApp footer